Filana Therapeutics
FLNA
Filana Therapeutics (FLNA) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$0.92
- EPS estimate
- $0.00
- EPS surprise
- +0.00%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 14, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 14, 2025 | $0.00 | −$0.92 | +0.00% | $0.00 | SEC |
| Q1 2025 | May 8, 2025 | $0.00 | −$0.48 | +0.00% | $0.00 | SEC |
| Q4 2024 | Mar 3, 2025 | −$0.58 | −$0.57 | +2.28% | $0.00 | SEC |
| Q3 2024 | Nov 7, 2024 | −$0.73 | −$0.58 | +20.55% | $0.00 | SEC |
| Q2 2024 | Aug 8, 2024 | −$0.41 | $0.13 | +131.96% | $0.00 | SEC |
| Q1 2024 | May 10, 2024 | −$0.46 | −$0.43 | +6.52% | $0.00 | SEC |
| Q4 2023 | Feb 28, 2024 | −$0.52 | −$0.50 | +3.85% | $0.00 | SEC |
| Q3 2023 | Nov 7, 2023 | −$0.78 | −$0.61 | +21.29% | $0.00 | SEC |
| Q2 2023 | Aug 3, 2023 | −$0.59 | −$0.63 | −6.78% | $0.00 | SEC |
| Q1 2023 | May 1, 2023 | −$0.56 | −$0.58 | −4.50% | $0.00 | SEC |
| Q4 2022 | Feb 28, 2023 | −$0.56 | −$0.47 | +16.07% | $0.00 | SEC |
| Q3 2022 | Nov 7, 2022 | −$0.48 | −$0.51 | −6.81% | $0.00 | — |
| Q2 2022 | Aug 3, 2022 | −$0.43 | −$0.48 | −10.98% | $0.00 | — |
| Q1 2022 | May 5, 2022 | −$0.42 | −$0.44 | −6.02% | $0.00 | — |
| Q4 2021 | Feb 28, 2022 | −$0.34 | −$0.35 | −4.48% | $0.00 | — |
| Q3 2021 | Nov 10, 2021 | −$0.15 | −$0.24 | −60.00% | $0.00 | — |
| Q2 2021 | Aug 3, 2021 | −$0.13 | −$0.13 | −1.56% | $0.00 | — |
| Q1 2021 | Apr 21, 2021 | −$0.09 | −$0.09 | −5.88% | $0.00 | — |
| Q4 2020 | Mar 23, 2021 | −$0.05 | −$0.09 | −89.47% | $0.00 | — |
| Q3 2020 | Nov 9, 2020 | −$0.07 | −$0.06 | +10.04% | $0.00 | — |
Quarterly revenue
Frequently asked questions
When did Filana Therapeutics (FLNA) last report earnings?
Filana Therapeutics last reported on Aug 14, 2025, covering fiscal Q2 2025.
Did FLNA beat earnings estimates?
Filana Therapeutics reported EPS of −$0.92 for Q2 2025, in line with the $0.00 consensus estimate.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.